Catalyst Pharmaceutical Partners Inc diskutieren
Catalyst Pharmaceutical Partners Inc
WKN: A0LCUL / Symbol: CPRX / Name: Catalyst Pharma / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
20,01 €
-1,34 %
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its "buy" rating re-affirmed by analysts at Bank of America Co.. They now have a $30.00 price target on the stock.
Ratings data for CPRX provided by MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its price target raised by analysts at HC Wainwright from $30.00 to $35.00. They now have a "buy" rating on the stock.
Ratings data for CPRX provided by MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for CPRX provided by MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $28.00 price target on the stock.
Ratings data for CPRX provided by MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its "overweight" rating re-affirmed by analysts at Stephens. They now have a $33.00 price target on the stock.
Ratings data for CPRX provided by MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Ratings data for CPRX provided by MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its price target raised by analysts at Robert W. Baird from $28.00 to $32.00. They now have an "outperform" rating on the stock.
Ratings data for CPRX provided by MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) was upgraded by analysts at Cantor Fitzgerald to a "strong-buy" rating.
Ratings data for CPRX provided by MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Ratings data for CPRX provided by MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Ratings data for CPRX provided by MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) had its "outperform" rating reaffirmed by analysts at Oppenheimer Holdings, Inc..
Ratings data for CPRX provided by MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) had its price target raised by analysts at Citigroup Inc. from $31.00 to $33.00. They now have a "buy" rating on the stock.
Ratings data for CPRX provided by MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Ratings data for CPRX provided by MarketBeat
Neueste Beiträge
TD_Securities in Bank of Montreal diskutieren